Recalls from Cipla USA, Inc.

• Cipla USA Fosfomycin Tromethamine Granules for Oral Solution (opens in a new tab)
  Moderate risk, FDA, Oct 6, 2026, Drug impurity
• Cipla Cinacalcet Hydrochloride Tablets (opens in a new tab)
  Moderate risk, FDA, Jul 2, 2026, Drug impurity
• Cipla Cinacalcet Hydrochloride Tablets (opens in a new tab)
  Moderate risk, FDA, Apr 10, 2026, Drug impurity
• Cipla Lanreotide Injection (opens in a new tab)
  Moderate risk, FDA, Apr 3, 2026, Sterility problem
• Cipla Nilotinib Capsules (opens in a new tab)
  Low risk, FDA, Mar 3, 2026, Quality testing problem

Data: Recall Canary (opens in a new tab)